eMedicine Specialties > Endocrinology > Metabolic Disorders
Glycogen Storage Disease, Type VI: Differential Diagnoses & Workup
Updated: Sep 21, 2007
- Overview
- Differential Diagnoses & Workup
- Treatment & Medication
- Follow-up
- Multimedia
Differential Diagnoses
| Glucose Intolerance | Hepatic Failure |
| Glucose-6-Phosphatase Deficiency | Hypoglycemia |
| Glucose-6-Phosphate Dehydrogenase
Deficiency | |
| Glycogen Storage Disease, Type Ib | |
| Hepatic Carcinoma, Primary |
Workup
Laboratory Studies
- Obtain a creatine kinase level in all cases of suspected glycogen storage disease (GSD).
- Because hypoglycemia may be found in some types of GSD, fasting glucose testing is indicated. In Hers disease, hypoglycemia is a primary concern.
- Urine studies are indicated because myoglobinuria may occur in some patients with GSDs.
- Hepatic failure occurs in some patients with GSDs, although rarely in those with Hers disease. Liver function studies are indicated and may reveal evidence of hepatic injury.
- Biochemical assay of enzyme activity is necessary for definitive diagnosis.
Imaging Studies
Findings from imaging studies may reveal hepatomegaly.
Other Tests
- Ischemic forearm test
- In the case of Hers disease, which is not associated with significant muscle involvement, the forearm ischemic test is most useful to help rule out other GSDs, most specifically Cori disease, McArdle disease, and Tarui disease. Test findings are expected to be negative in patients with Hers disease.
- The ischemic forearm test is an important tool for diagnosis of muscle disorders. The basic premise is an analysis of the normal chemical reactions and products of muscle activity. Obtain consent before the test.
- Instruct the patient to rest. Position a loosened blood pressure cuff on the arm, and place a venous line for blood samples in the antecubital vein.
- Obtain blood samples for the following tests: creatine kinase, ammonia, and lactate. Repeat in 5-10 minutes.
- Obtain a urine sample for myoglobin analysis.
- Immediately inflate the blood pressure cuff above systolic blood pressure and have the patient repetitively grasp an object, such as a dynamometer. Instruct the patient to grasp the object firmly, once or twice per second. Encourage the patient for 2-3 minutes, at which time the patient may no longer be able to participate. Immediately release and remove the blood pressure cuff.
- Obtain blood samples for creatine kinase, ammonia, and lactate immediately and at 5, 10, and 20 minutes.
- Collect a final urine sample for myoglobin analysis.
- Interpretation of ischemic forearm test results
- With exercise, carbohydrate metabolic pathways yield lactate from pyruvate. Lack of lactate production during exercise is evidence of a pathway disturbance, and an enzyme deficiency is suggested. In such cases, muscle biopsy with biochemical assay is indicated.
- Healthy patients demonstrate an increase in lactate of at least 5-10 mg/dL and ammonia of at least 100 mcg/dL. Levels will return to baseline.
- If neither level increases, the exercise was not strenuous enough and the test is not valid.
- Increased lactate at rest (before exercise) is evidence of mitochondrial myopathy.
- Failure of lactate to increase with ammonia is evidence of a GSD resulting in a block in carbohydrate metabolic pathways. Not all patients with GSDs have positive ischemic test results.
- Failure of ammonia to increase with lactate is evidence of myoadenylate deaminase deficiency.
- Positive ischemic forearm test results may occur in patients with Cori disease, McArdle disease, and Tarui disease.
- In patients with Hers disease, ischemic test results are negative.
Procedures
Liver biopsy may be required to diagnose the cause of hepatomegaly.
More on Glycogen Storage Disease, Type VI |
| Overview: Glycogen Storage Disease, Type VI |
Differential Diagnoses & Workup: Glycogen Storage Disease, Type VI |
| Treatment & Medication: Glycogen Storage Disease, Type VI |
| Follow-up: Glycogen Storage Disease, Type VI |
| Multimedia: Glycogen Storage Disease, Type VI |
| References |
| « Previous Page | Next Page » |
References
Zingone A, Hiraiwa H, Pan CJ. Correction of glycogen storage disease type 1a in a mouse model by gene therapy. J Biol Chem. Jan 14 2000;275(2):828-32. [Medline].
Bijvoet AG, Van Hirtum H, Vermey M. Pathological features of glycogen storage disease type II highlighted in the knockout mouse model. J Pathol. Nov 1999;189(3):416-24. [Medline].
Asami T, Kikuchi T, Asami K. Effect of clonidine on the height of a child with glycogen storage disease type VI: a 13 year follow-up study. Acta Paediatr Jpn. Oct 1996;38(5):524-8. [Medline].
Amato AA. Acid maltase deficiency and related myopathies. Neurol Clin. Feb 2000;18(1):151-65. [Medline].
Aminoff MJ, ed. Electromyography in Clinical Practice. 3rd ed. New York, NY: Churchill Livingstone; 1998.
Applegarth DA, Toone JR, Lowry RB. Incidence of inborn errors of metabolism in British Columbia, 1969-1996. Pediatrics. Jan 2000;105(1):e10. [Medline].
Burwinkel B, Bakker HD, Herschkovitz E. Mutations in the liver glycogen phosphorylase gene (PYGL) underlying glycogenosis type VI. Am J Hum Genet. Apr 1998;62(4):785-91. [Medline].
Chen Y. Glycogen Storage Diseases. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Vogelstein B, eds. The Metabolic and Molecular Bases of Inherited Disease. Vol 1. 8th ed. New York, NY: McGraw-Hill; 2000:1537-8.
DiMauro S, Bruno C. Glycogen storage diseases of muscle. Curr Opin Neurol. Oct 1998;11(5):477-84. [Medline].
Goldberg T, Slonim AE. Nutrition therapy for hepatic glycogen storage diseases. J Am Diet Assoc. Dec 1993;93(12):1423-30. [Medline].
Orho M, Bosshard NU, Buist NR. Mutations in the liver glycogen synthase gene in children with hypoglycemia due to glycogen storage disease type 0. J Clin Invest. Aug 1 1998;102(3):507-15. [Medline].
Smit GP, Fernandes J, Leonard JV. The long-term outcome of patients with glycogen storage diseases. J Inherit Metab Dis. 1990;13(4):411-8. [Medline].
Stevens AN, Iles RA, Morris PG. Detection of glycogen in a glycogen storage disease by 13C nuclear magnetic resonance. FEBS Lett. Dec 27 1982;150(2):489-93. [Medline].
Tang NL, Hui J, Young E, et al. A novel mutation (G233D) in the glycogen phosphorylase gene in a patient with hepatic glycogen storage disease and residual enzyme activity. Mol Genet Metab. Jun 2003;79(2):142-5. [Medline].
Wolfsdorf JI, Holm IA, Weinstein DA. Glycogen storage diseases. Phenotypic, genetic, and biochemical characteristics, and therapy. Endocrinol Metab Clin North Am. Dec 1999;28(4):801-23. [Medline].
Further Reading
Keywords
Hers disease, glycogen storage disease type VI, GSD type VI, enzyme defect, hepatomegaly, hypoglycemia, liver phosphorylase deficiency, glycogen storage disease, GSD, Hers' disease, GSD type 0, glycogen synthase deficiency, GSD type Ia, glucose-6-phosphatase deficiency, G-6-P deficiency, von Gierke disease, GSD type II, acid maltase deficiency, Pompe disease, GSD type III, debranching enzyme deficiency, Forbes-Cori disease, GSD type IV, GSD type V, myophosphorylase deficiency, McArdle disease, transglucosidase deficiency, Andersen disease, amylopectinosis, GSD type VII, phosphofructokinase deficiency, Tauri disease
Differential Diagnoses & Workup: Glycogen Storage Disease, Type VI